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Add Sweet’s Syndrome to your dermatologic
differential
Michael Waddick, MD Elizabeth Deyo, MD

INTRODUCTION
Sweet syndrome is a rare inflammatory disease that is
marked by abrupt onset of painful erythematous plaques or
nodules and often accompanied by fever and leukocytosis.
While there is considered to be three types of Sweet’s
syndrome; classical, malignancy associated, and druginduced, the most common type remains classical4. Classical
Sweet’s syndrome is associated most commonly with URI or
GI infections, inflammatory bowel disease, or pregnancy
though less frequent associations exist with several other
medical conditions. Malignancy associated Sweet’s syndrome
is most commonly associated with hematologic malignancies
however it has been detected in solid tumor cancer as well.
Drug-induced Sweet Syndrome has been associated with
several medications however Granulocyte-colony stimulating
factor is the most commonly recognized6. Sweet syndrome
can develop in any age patient, although age 30-60 is most
common for classical. In Classical Sweet syndrome, 80% of
cases have been in women. in women.

MANAGEMENT
Once a diagnosis of Sweet’s syndrome is established, management should focus on identifying
underlying infection or disease processes, eliminating any precipitating drug exposure, and
evaluation for malignancy including age-appropriate screening. Corticosteroid therapy is the firstline treatment for Sweet’s syndrome and often induces rapid clinical response. Oral prednisone
started at 0.5 to 1mg/kg per day often produces clinical improvement within 48 hours and lesions
often resolve within 2 weeks. After the disease is controlled, the prednisone dose can be tapered
over 4-6 weeks (1). Although most patients will need systemic corticosteroids, a minority with
small localized cutaneous lesions may respond to high dose topical steroids. When avoidance of
systemic corticosteroids is needed, alternative first line therapies include colchicine, dapsone and
potassium iodide have efficacy based on case reports and retrospective studies (2).

CASE REVIEW
History
Patient is a 44 year old male who presented with an area of painful
erythema on the dorsum of right ankle, left ankle and foot, back of
neck, and dorsal bilateral middle fingers extending to wrists.
All the above joints painful to move, and difficult to ambulate. The
area on the back of his neck and occipital scalp were last to erupt
and are not as painful.
+Fatigue, malaise, subjective chills
No new medications
No fever (+subjective chills), no abdominal
pain/nausea/vomit/diarrhea/constipation
PMH: HIV (last viral load 84copies/ml 2018), syphilis (distantly
treated),Type 2 Diabetes Mellitus, social anxiety, low testosterone,
hyperlipidemia
Medications: abacavir-dolutegravir-lamivudine, atorvastatin,
bupropion, fluoxetine, semaglutide, testosterone cypionate IM
Physical Exam
128/72, 96, 16, 98.3F, O2 98%RA. 226lb 12.8oz, 5ft 11.5in
Gen: well nourished, appears fatigued but no acute distress
HEENT: oral mucosa moist/pink without lesions. Neck supple, no
lymphadenopathy except bilateral <1cm moveable occipital nodes
Extremities: Right wrist with dorsal erythema, mild edema, bilateral
middle digits with mild edema and violaceous skin discoloration.
MCP, wrists and ankles with bilateral erythema, stiff and painful on
active and passive rom
Skin: see above for skin changes overlying joints. Neck and occipital
scalp with erythematous plaques with raised well-defined borders. No
fluctuence or tenderness in this area. Skin changes overlying joints
painful to palpation (see photos)
Assessment/Plan
44 year old HIV positive male distantly treated for syphilis, with new
onset rash, chills and polyarthritis/polyarthralgias
Differential diagnosis included vasculitis, syphilis, reactive arthritis,
sweet’s syndrome
Biopsy obtained of right ankle and neck lesions
RPR titer, cbc with differential, cmp, blood cultures, CRP, HIV RNA
Outcome/Follow up
Biopsy: neutrophilic dermatosis consistent with Sweet’s
Syndrome. Pertinent lab data: RPR 1:2, CRP 32.9 mg/dl, WBC
14.5.
Treatment: Oral prednisone 1 mg/kg/day. Within three days, the
patient had clinical improvement. Prednisone was tapered over six
weeks and the patient’s rash and symptoms did not recur.

DISCUSSION
This case provides an excellent example of Sweet’s
Syndrome and its clinical considerations. A 44 year old
male HIV positive patient presented with arthralgias, chills,
malaise and a plaque-like rash on the back of his neck,
head and wrist. The biopsy confirmed neutrophilic
dermatosis consistent with Sweet’s Syndrome. It is
extremely important to consider the possible causes of
Sweet’s Syndrome, while the diagnosis is being established
and treatment is initiated. Our patient was up to date on
preventative cancer screening for his age, and thorough
physical exam did not reveal any suspicion for occult
malignancy. He had no antecedent or concurrent acute
infection to precipitate Sweet’s Syndrome. With respect to
medications, Abacavir is known to cause neutrophilic
dermatosis, but the patient had been on this medication for
greater than one year, and there was not a strong temporal
relationship between drug initiation and onset of symptoms.
Additional evidence against Abacavir as a causative agent
included no recurrence when prednisone was tapered even
though patient was continued on Abacavir. There are few
case reports of Sweet’s Syndrome associated with HIV
infection, but a causal relationship has not been established
(3). Consideration was given to syphilis infection, but
patient was previously treated and had no increase in his
titers. The clinical opinion of our team and the consulting
dermatologist was that this case was idiopathic.

KEY LEARNING POINTS

Ref: Cohen, Philip. Sweet’s Syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2: 34.

Consider Sweet’s Syndrome in the differential diagnosis of any
patient who presents with the abrupt onset of painful
erythematous papules, plaques or nodules.
Major diagnostic criteria:
1) Abrupt onset of painful erythematous plaques or nodules.
2) Histopathologic evidence of dense neutrophilic infiltrate
without evidence of leukocytoclastic vasculitis.
Minor diagnostic criteria (need two):
1) Pyrexia >38C.
2) Association with underlying hematologic or visceral
malignancy, inflammatory disease for pregnancy, or
preceded by URI or vaccination.
3) Excellent response to treatment with systemic
glucocorticoids or potassium iodide.
4) Abnormal lab studies
The mainstay of treatment is corticosteroids and improvement
is often seen within 48 hours. Steroid dose is tapered over 4 to
6 weeks.
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